Last reviewed · How we verify

NCT03579797: SDES

Shanghai Diabetic Eye Study in Diabetics

Status unknown Last updated 9 July 2018
What this trial tests

trial testing Screening, referral, follow-up and health management in Diabetic Eye Diseases in 200,000 participants. Status unknown.

Timeline
1 January 2015
Primary endpoint
31 December 2018
31 December 2018

Quick facts

Lead sponsorShanghai Eye Disease Prevention and Treatment Center
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment200,000
Start date1 January 2015
Primary completion31 December 2018
Estimated completion31 December 2018
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Shanghai Eye Disease Prevention and Treatment Center — full company profile →

Who can join

35 and older, any sex, with Diabetic Eye Diseases or Diabetic Retinopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the Shanghai Diabetic Eye Study (SDES) was to guide and regulate eye health screening of two hundred thousand people with diabetes in the communities in 16 districts in Shanghai, build up the ranks with the general practitioner as the backbone combined, and provide comprehensive, continuous, and dynamic information service to diabetic eye disease health management. We expect to form a "screening, finding, referral, follow-up and health management" diabetic eye disease working mode, integrate medical care and precaution closely, promote the classified management and referral, reduce the prevalence rate of diabetic eye disease, blindness and visual impairment of DR, and improve diabetics consciousness of eye health maintenance. At the same time, we will also improve the device configuration of eye health screening and relevant personnel training mechanism in the community health service centers, thus upgrading the level of eye disease prevention and treatment in Shanghai.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The diagnostic accuracy of an intelligent and automated fundus disease image assessment system with lesion quantitative function (SmartEye) in diabetic patients.
    Xu Y, Wang Y, Liu B, Tang L, et al · · 2019 · cited 27× · PMID 31412800 · DOI 10.1186/s12886-019-1196-9

Verify or expand the search:

Other Shanghai Eye Disease Prevention and Treatment Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03579797.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing